Abstract # 2450 Impact of Chemotherapy on Parotid Dose-Volume Tolerance in Patients Treated with Intensity-Modulated Radiation Therapy for Head & Neck Cancers (HNC)

Presenter: Parikh, Simul

< Back to topics

> Cover Page, Authors, Institutions

> Purpose/Objective

> Materials/Methods

> Results/Discussion

> Conclusions

> View tables/images/videos


Results:
The median MPD for patients treated with RT alone compared to patients treated with ChRT were 30.1 and 24.4 Gy, respectively (p=0.0001). There were two grade 4 toxicities, and excluding them did not change the outcome. For patients with a MPD <26 Gy, the rate of grade 2-3 acute xerostomia was 21.2%, compared to 44.5% for patients with a MPD of >26 (p=0.02). For patients with a MPD <26 Gy, the rate of grade 2-3 late xerostomia was 6.5%, compared to 19% for those with a MPD of >26 (p=0.11). For patients receiving RT alone, the rate of grade 2-3 acute xerostomia was 34.3%, compared to 22.3% for those receiving ChRT (p=0.002). For patients receiving RT alone, the rate of grade 2-3 late xerostomia was 13.2%, compared to 8.8% in those receiving ChRT. For patients with an MPD <26 Gy, the grade 2-3 acute toxicity was 14.6% when treated with RT alone vs. 27.4% in those treated with ChRT (p=0.01). For patients with an MPD <26 Gy, the grade 2-3 chronic toxicity was 3.2% when treated with RT alone, compared to 9.6% in those receiving ChRT (p=0.28).